Literature DB >> 16189125

Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.

Christof von Eiff1, Alexander W Friedrich, Karsten Becker, Georg Peters.   

Abstract

The antistaphylococcal activity of ceftobiprole was compared with those of cefuroxime, linezolid, and moxifloxacin by using the agar dilution method. Apart from three strains with small-colony variant phenotypes, all Staphylococcus aureus isolates tested were inhibited by < or =2 microg/ml of ceftobiprole. This compound exhibited an excellent antistaphylococcal activity, comparable to that of linezolid.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16189125      PMCID： PMC1251552          DOI： 10.1128/AAC.49.10.4372-4374.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Authors:  Ronald N Jones; Lalitagauri M Deshpande; Alan H Mutnick; Douglas J Biedenbach
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management.

Authors:  Dag Harmsen; Heike Claus; Wolfgang Witte; Jörg Rothgänger; Hermann Claus; Doris Turnwald; Ulrich Vogel
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

3.  Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.

Authors:  Lalitagauri Deshpande; Paul R Rhomberg; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

4.  Recovery of small colony variants of Staphylococcus aureus following gentamicin bead placement for osteomyelitis.

Authors:  C von Eiff; D Bettin; R A Proctor; B Rolauffs; N Lindner; W Winkelmann; G Peters
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

5.  Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.

Authors:  Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.

Authors:  C von Eiff; G Peters
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

7.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with darier's disease.

Authors:  C von Eiff; K Becker; D Metze; G Lubritz; J Hockmann; T Schwarz; G Peters
Journal:  Clin Infect Dis       Date:  2001-04-30       Impact factor: 9.079

9.  Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction.

Authors:  K Murakami; W Minamide; K Wada; E Nakamura; H Teraoka; S Watanabe
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

10.  Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants.

Authors:  Nicole Baumert; Christof von Eiff; Franziska Schaaff; Georg Peters; Richard A Proctor; Hans-Georg Sahl
Journal:  Microb Drug Resist       Date:  2002       Impact factor: 3.431
View more
  12 in total

1.  In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.

Authors:  Olivier Denis; Ariane Deplano; Claire Nonhoff; Marie Hallin; Raf De Ryck; Raymond Vanhoof; Ricardo De Mendonça; Marc J Struelens
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections.

Authors:  Jill M Butterfield; Brian T Tsuji; Jack Brown; Elizabeth Dodds Ashley; Dwight Hardy; Kristen Brown; Alan Forrest; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 3.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 4.  Coagulase-negative staphylococci.

Authors:  Karsten Becker; Christine Heilmann; Georg Peters
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 5.  Clinical Infections, Antibiotic Resistance, and Pathogenesis of Staphylococcus haemolyticus.

Authors:  Hala O Eltwisy; Howida Omar Twisy; Mahmoud Hr Hafez; Ibrahim M Sayed; Mohamed A El-Mokhtar
Journal:  Microorganisms       Date:  2022-05-31

Review 6.  Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.

Authors:  Bindu Murthy; Anne Schmitt-Hoffmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.

Authors:  César Bustos; Jose L Del Pozo
Journal:  Infect Drug Resist       Date:  2010-04-22       Impact factor: 4.003

8.  De Novo Emergence of Peptides That Confer Antibiotic Resistance.

Authors:  Michael Knopp; Jonina S Gudmundsdottir; Tobias Nilsson; Finja König; Omar Warsi; Fredrika Rajer; Pia Ädelroth; Dan I Andersson
Journal:  mBio       Date:  2019-06-04       Impact factor: 7.867

9.  Cefuroxime plasma and tissue concentrations in patients undergoing elective cardiac surgery: Continuous vs bolus application. A pilot study.

Authors:  Keso Skhirtladze-Dworschak; Doris Hutschala; Georg Reining; Peter Dittrich; Anna Bartunek; Martin Dworschak; Edda M Tschernko
Journal:  Br J Clin Pharmacol       Date:  2019-02-13       Impact factor: 4.335

10.  Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype.

Authors:  Brian T Tsuji; Christof von Eiff; Pamela A Kelchlin; Alan Forrest; Patrick F Smith
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.